Anti-HIV Drug Elvitegravir enhanced the ubiquitination degradation of METTL3 by promoting the interaction between METTL3 and E3 ubiquitin ligase STUB1, which confirmed that the drug has a significant inhibitory effect on ESCC invasion and metastasis [81]. This evidence concerns the gene METTL3 and esophageal squamous cell carcinoma.